Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.
暂无分享,去创建一个
Martin Widschwendter | Christian Marth | Peter W Laird | Georg Goebel | P. Laird | M. Widschwendter | H. Fiegl | C. Marth | E. Müller-Holzner | G. Goebel | Heidi Fiegl | Simone Millinger | Elisabeth Müller-Holzner | Simone Millinger
[1] P. Laird,et al. MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.
[2] M. Polymeropoulos,et al. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. , 2003, Cancer research.
[3] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[4] J. Minna,et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. , 2001, Cancer research.
[5] M. Widschwendter,et al. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status , 2003, British Journal of Cancer.
[6] D. Miles,et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer , 1999, British Journal of Cancer.
[7] Martin Widschwendter,et al. DNA methylation and breast carcinogenesis , 2002, Oncogene.
[8] A. Sbarbati,et al. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells. , 2005, Carcinogenesis.
[9] D B Evans,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Martin Widschwendter,et al. Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.
[11] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Fernand Labrie,et al. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology , 1997, Steroids.
[13] N. Davidson,et al. DNA methylation in breast cancer. , 2001, Endocrine-related cancer.
[14] Victor X Jin,et al. Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer , 2004, Cancer Research.
[15] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.
[16] Satoshi Matsumoto,et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.
[17] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[18] W D Flanders,et al. The lifetime risk of developing breast cancer. , 1993, Journal of the National Cancer Institute.
[19] M. Campiglio,et al. Role of HER2 gene overexpression in breast carcinoma , 2000, Journal of cellular physiology.
[20] Joseph Geradts,et al. Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. , 2002, The American journal of pathology.
[21] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. M. Chen,et al. Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.
[23] Martin Widschwendter,et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. , 2005, Cancer research.
[24] O. Monni,et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.
[25] Daniel Birnbaum,et al. Identification and validation of an ERBB2 gene expression signature in breast cancers , 2004, Oncogene.
[26] Jun Yao,et al. Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.